Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies

A. Mengarelli, A. P. Lori, C. Guglielmi, M. P. Perrone, M. Gozzer, C. Girmenia, G. Cimino, A. M. Testi, R. Ricci, L. De Felice, G. Girelli, F. Mandelli, W. Arcese

Research output: Contribution to journalArticlepeer-review


Twenty-nine consecutive patients with high-risk hematological malignancy aged from 3 to 58 years underwent an unmanipulated graft from an HLA-identical sibling after an irradiation-free preparative regimen consisting of idarubicin (IDA), 21 mg/m2/day administered by continuous infusion on days - 12 and -11, followed by busulphan (BU), 4 mg/kg/day orally from day -7 to -4, and cyclophosphamide (CY), 60 mg/kg/day intravenously on days -3 and -2 (IDA-BUCY2). Most clinically relevant extra-hematological regimen-related toxicities consisted of stomatitis observed in all subjects and hemorrhagic cystitis occurred in five cases (17%) within 100 days after transplant. Six patients (21%) developed a grade 2 acute graft-versus-host disease (GVHD) and three (10%) a grade 3 or 4; extensive chronic GVHD was assessed in nine of 22 (41%) evaluable patients. So far, 12 patients have died and 17 are alive, 16 of whom disease-free, 5-41 months after transplant (median, 15 months). The causes of death were related to GVHD in three patients, to sepsis in one and to disease recurrence in the remaining eight. At present, only one of nine relapsed patients is alive. For all patients the actuarial probability of survival (OS) at 1 and 2 years ± standard error (s.e.) was 63 ± 9% and 52 ± 10%, respectively. The actuarial probabilities of disease-free survival (DFS), relapse and transplant-related mortality (TRM) at both 1 and 2 years ± s.e. were 53 ± 9%, 35 ± 9% and 16 ± 7%, respectively. These results are encouraging but not substantially different from those obtained in 28 patients with malignancy in advanced phase transplanted after the standard BUCY2 regimen, who had an actuarial probability of OS, DFS, relapse and TRM projected at 10 years ± s.e. of 54 ± 10%, 57 ± 9%, 36 ± 9% and 11 ± 6%, respectively. Although the retrospective comparison between the two groups does not seem to show any advantage in the use of the IDA intensified regimen, only a prospective randomized trial could answer this question.

Original languageEnglish
Pages (from-to)2052-2058
Number of pages7
Issue number12
Publication statusPublished - 2000


  • Allogeneic BMT
  • High-risk malignancies

ASJC Scopus subject areas

  • Hematology
  • Cancer Research


Dive into the research topics of 'Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies'. Together they form a unique fingerprint.

Cite this